Intellectus Partners LLC Raises Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Intellectus Partners LLC boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 26.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 74,525 shares of the company’s stock after acquiring an additional 15,700 shares during the period. Intellectus Partners LLC’s holdings in Intellia Therapeutics were worth $869,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. E Fund Management Co. Ltd. increased its position in Intellia Therapeutics by 10.0% during the 4th quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company’s stock worth $210,000 after purchasing an additional 1,634 shares in the last quarter. Vestmark Advisory Solutions Inc. boosted its stake in shares of Intellia Therapeutics by 14.3% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 375,291 shares of the company’s stock worth $4,376,000 after purchasing an additional 47,045 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth about $4,793,000. Arizona State Retirement System raised its position in shares of Intellia Therapeutics by 6.1% in the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company’s stock valued at $327,000 after buying an additional 1,615 shares during the last quarter. Finally, Aigen Investment Management LP purchased a new position in shares of Intellia Therapeutics during the fourth quarter valued at approximately $213,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Analyst Upgrades and Downgrades

NTLA has been the subject of several recent analyst reports. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research note on Monday, March 3rd. BMO Capital Markets lowered their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. HC Wainwright initiated coverage on Intellia Therapeutics in a research report on Wednesday. They set a “buy” rating and a $30.00 target price on the stock. Wedbush reissued a “neutral” rating and issued a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $37.56.

Intellia Therapeutics Trading Up 4.5 %

Shares of NASDAQ:NTLA opened at $10.35 on Friday. The stock has a market capitalization of $1.07 billion, a PE ratio of -1.90 and a beta of 1.97. Intellia Therapeutics, Inc. has a 1 year low of $8.30 and a 1 year high of $32.00. The firm has a fifty day moving average price of $10.61 and a 200 day moving average price of $15.19.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the sale, the chief executive officer now owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In the last three months, insiders have sold 29,000 shares of company stock worth $352,551. 3.20% of the stock is owned by insiders.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.